Doctor warns 'dangerous' leftover rice and pasta mistake is putting lives at risk
A doctor has warned the public about the dangers of improperly storing leftover rice and pasta.
It's common practice to save excess food or takeaway for the next day to avoid wastage. The process for most foods is straightforward: let it cool, then refrigerate.
However, an American ER doctor, Joe Whittington, has raised alarm bells about preserving any dishes containing rice or pasta. In a TikTok video, he reacted to another user's post recounting the tragic tale of a 20-year-old man who died after consuming five-day-old pasta that hadn't been refrigerated.
The young man was studying in Belgium when he tragically lost his life in 2008 after eating spaghetti leftovers, which he had prepared five days earlier and left out at room temperature instead of refrigerating.
Soon after consuming the pasta, he fell ill with severe vomiting and gastrointestinal symptoms, and by the following morning, he was found dead. An autopsy revealed acute liver failure, and tests showed high levels of a bacterium known as Bacillus cereus in the pasta, according to the Journal of Clinical Microbiology.
In his video, Dr Joe cautioned that although most of us wouldn't eat five-day-old pasta anyway, Bacillus cereus can develop in pasta and rice dishes rapidly, exposing you to risks within hours rather than days.
He elaborated: 'This 20-year-old man died of a condition that's commonly referred to as 'fried rice syndrome'. This is a condition in which you have bacterial overgrowth if pasta or rice is left at room temperature for too long.
'In medical school, we're taught the phrase 'Reheat rice? Be serious!' to remember which bacteria [b. cereus] causes this condition.
'So, how long is too long? You should not eat pasta or rice left at room temperature, unrefrigerated, for more than two hours.'
The NHS advises that rice should be cooled within an hour of cooking and then immediately stored in the fridge or freezer. It should also be consumed within 24 hours and never reheated more than once.
Viewers of Dr Joe's video had mixed reactions. Many claimed they've never fallen ill after consuming pasta or rice that has been left at room temperature for over two hours.
However, some highlighted that the two-hour rule doesn't guarantee food poisoning or death from eating rice or pasta left on the kitchen counter. This is merely when the bacteria begin to multiply, meaning your risk of food poisoning escalates the longer it is left out. What to do if you have food poisoning
Food poisoning is typically not severe and generally improves within a week. Symptoms such as vomiting and diarrhoea can often be managed at home, with the key being to stay hydrated to avoid dehydration.
It's also crucial to get plenty of rest and eat when possible – but steer clear of fatty or spicy foods, which could further irritate your sensitive stomach. The NHS also recommends avoiding fruit juice or fizzy drinks, as these can exacerbate diarrhoea.
You should call 111 if: You're worried about a baby under 12 months
A child under five years has signs of dehydration (such as fewer wet nappies)
You or your child have signs of dehydration after using oral rehydration sachets
You or your child keep being sick and cannot keep fluid down
You or your child have bloody diarrhoea or bleeding from the bottom
You or your child have diarrhoea for more than 7 days or vomiting for more than 2 days
You should call 999 if you or your child: Vomit blood or have vomit that looks like ground coffee
Have green vomit (adults)
Have yellow-green or green vomit (children)
May have swallowed something poisonous
Have a stiff neck and pain when looking at bright lights
Have a sudden, severe headache
Have a sudden, severe tummy ache
Have blue, grey, pale or blotchy skin, lips or tongue – on brown or black skin, this may be easier to see on the palms of the hands or soles of the feet
Are having severe difficulty breathing, or taking lots of quick, short breaths
Are confused or not responding as usual
You can find more information on food poisoning via the NHS website.
READ SOURCE
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Weight loss pill set to rival injections after promising studies
A new daily weight loss pill has shown promising results in initial studies. Researchers say amycretin, which can be offered by injection or tablet, helped patients lose a significant amount of weight in the first trials. Those who received higher doses of amycretin as a weekly jab lost 24.3 per cent of their body weight after 36 weeks of treatment, while patients who took daily tablets lost an average of 13.1 per cent of their body weight after 12 weeks. While weight loss jabs have been hailed as transformative by NHS leaders, injections come with additional work for over-stretched health services, so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3 per cent after 36 weeks of treatment. It also showed signs of improving blood sugar levels. Side effects included nausea and vomiting, and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1 per cent of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7 per cent, with a third of participants losing 25 per cent or more of their body weight after 72 weeks.
Yahoo
7 hours ago
- Yahoo
ChatGPT use linked to cognitive decline, research reveals
Relying on the artificial intelligence chatbot ChatGPT to help you write an essay could be linked to cognitive decline, a new study reveals. Researchers at the Massachusetts Institute of Technology Media Lab studied the impact of ChatGPT on the brain by asking three groups of people to write an essay. One group relied on ChatGPT, one group relied on search engines, and one group had no outside resources at all. The researchers then monitored their brains using electroencephalography, a method which measures electrical activity. The team discovered that those who relied on ChatGPT — also known as a large language model — had the 'weakest' brain connectivity and remembered the least about their essays, highlighting potential concerns about cognitive decline in frequent users. 'Over four months, [large language model] users consistently underperformed at neural, linguistic, and behavioral levels,' the study reads. 'These results raise concerns about the long-term educational implications of [large language model] reliance and underscore the need for deeper inquiry into AI's role in learning.' The study also found that those who didn't use outside resources to write the essays had the 'strongest, most distributed networks.' While ChatGPT is 'efficient and convenient,' those who use it to write essays aren't 'integrat[ing] any of it' into their memory networks, lead author Nataliya Kosmyna told Time Magazine. Kosmyna said she's especially concerned about the impacts of ChatGPT on children whose brains are still developing. 'What really motivated me to put it out now before waiting for a full peer review is that I am afraid in 6-8 months, there will be some policymaker who decides, 'let's do GPT kindergarten,'' Kosmyna said. 'I think that would be absolutely bad and detrimental. Developing brains are at the highest risk.' But others, including President Donald Trump and members of his administration, aren't so worried about the impacts of ChatGPT on developing brains. Trump signed an executive order in April promoting the integration of AI into American schools. 'To ensure the United States remains a global leader in this technological revolution, we must provide our Nation's youth with opportunities to cultivate the skills and understanding necessary to use and create the next generation of AI technology,' the order reads. 'By fostering AI competency, we will equip our students with the foundational knowledge and skills necessary to adapt to and thrive in an increasingly digital society.' Kosmyna said her team is now working on another study comparing the brain activity of software engineers and programmers who use AI with those who don't. 'The results are even worse,' she told Time Magazine. The Independent has contacted OpenAI, which runs ChatGPT, for comment.
Yahoo
8 hours ago
- Yahoo
Weight loss pill shows promise in new trial
A new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight, studies suggest. An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
